TLX
Telix Pharmaceuticals LimitedNASDAQ
Healthcare • Biotechnology
Updated 1 day ago
Coverage ready
Factor tilt: Anti-Growth Mid Cap
$10.92-3.28%
Close Oct 13, 2026
- Market cap
- $3.9B
- 1 month
- -7.3%
- 3 months
- -3.3%
- 1 year
- +14.1%
- 52-week range
- $6.41$12.83
- Dividend
- No dividends on record
- Short interest
- 0.2% of float426.8K shares · settled Sep 30, 2026 · +21.1% since Sep 15, 2026 · FINRA
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if TLX is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
9 top institutions tracked
as of 2026-Q2 (filed 2026-09-09)
Last 13F trend: distributing (heavy)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: neutral
Last trade: buy 30 days ago
Red flags: 3
Largest 13-F holders · Q2 2026
62 filers reported a long position in TLX for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| FMR LLC | $6.5M | 561.2K | -0.6% |
| LAZARD ASSET MANAGEMENT LLC | $3.3M | 284.2K | -2% |
| PORTLAND INVESTMENT COUNSEL INC. | $3.1M | 266.2K | Unchanged |
| Private Advisor Group, LLC | $2.3M | 197.3K | +13.1% |
| MARSHALL WACE, LLP | $2.2M | 189.2K | New |
| MORGAN STANLEY | $1.9M | 166K | +42.5% |
| Integrated Wealth Concepts LLC | $1.9M | 164.4K | Unchanged |
| Hennion & Walsh Asset Management, Inc. | $1.7M | 150.1K | New |
| UBS Group AG | $1.6M | 134.7K | +317% |
| BLAIR WILLIAM & CO/IL | $1.4M | 123K | New |
Get the Full Analysis for TLX
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.